RET and breast cancer: Albeit rare, an ERBB2 fusion identified in a patient with HER2+ breast cancer and an acquired RET fusion identified in a patient with an acquired ESR1, offer interesting insights into subtype-specific resistance mechanisms and warrant further investigation.